Physician profile
Debra E Davis
NPI 1326064148
$15,736.51
in general payments reported to CMS, 2019-2025
46 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $1,118 · 2021: $2,790 · 2022: $3,365 · 2023: $2,639 · 2024: $3,196 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,944.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,734.72 | 2019-2024 | Nuplazid, Daybue |
| Abbvie INC. | $1,728.14 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,089.80 | 2019-2025 | |
| Allergan, INC. | $990.89 | 2019-2022 | |
| Biogen, INC. | $985.41 | 2019-2024 | Spinraza, Vumerity, Tysabri |
| Amgen INC. | $912.46 | 2019-2025 | Uplizna, Aimovig |
| Alexion Pharmaceuticals, INC. | $774.25 | 2019-2024 | Ultomiris, Soliris |
| Horizon Therapeutics Plc | $760.66 | 2021-2023 | Uplizna |
| Genzyme Corporation | $699.08 | 2019-2023 | |
| Emd Serono, INC. | $546.99 | 2019-2024 | Mavenclad |
| Biohaven Pharmaceuticals, INC. | $512.69 | 2020-2021 | |
| Pfizer INC. | $388.85 | 2023-2024 | |
| Ucb, INC. | $383.84 | 2021-2024 | Briviact, Fintepla, Nayzilam |
| Sk Life Science, INC. | $359.36 | 2021-2024 | |
| Argenx US, INC. | $355.54 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.